ReviewOncology letters2022
Function of BCLAF1 in human disease.
Review in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Circulating MicroRNAs as Diagnostic and Prognostic Biomarkers for Neuroblastoma: A Systematic Review and Exploratory Re-analysis.Molecular diagnosis & therapy · 2026Pooled it
- HO-1 Nuclear Interactome Implications in Neuroendocrine Transdifferentiation in Prostate Cancer.International journal of molecular sciences · 2026Article
- Perifollicular stromal cells sustain folliculogenesis via MDK-NCL signaling in mice and humans.Cell discovery · 2026Article
- Bclaf1 drives heart failure by recruiting Srsf2 to enhance Hand2 pre-mRNA splicing and pathological hypertrophy.Nature communications · 2026Article
- Research progress on the roles and mechanisms of flavonoid monomers in liver diseases: a review.Molecular biology reports · 2026Review
- Dynamic epigenetic regulation of BCLAF1 splicing in acute myeloid leukemia.Cell death & disease · 2026Article
- BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia.bioRxiv : the preprint server for biology · 2026Article
- FGF7-FGFR2 Signaling Enhances Contractile Activation of CAFs in Ovarian Cancer: Integrative Single-Cell and Spatial Transcriptomics.Journal of inflammation research · 2026Article
- PA28γ-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma.Cellular & molecular immunology · 2026Article
- Phosphoproteomic Analysis Reveals Differences in Intercellular Spread Among Feline Herpesvirus Type 1 Mutants.Veterinary sciences · 2025Article
- Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.Pharmaceutics · 2025Article
- A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells.Cell death & disease · 2025Article
- A novel MIR100HG transcript enhances tumorigenesis by inducing BCLAF1-mediated alternative splicing in colorectal cancer.Cell communication and signaling : CCS · 2025Article
- New Anti-Fibrotic Strategies for Keloids: Insights From Single-Cell Multi-Omics.Cell proliferation · 2025Article
- Pan-Cancer Analysis Identifies BCLAF1 as a Potential Biomarker for Renal Cell Carcinoma.Biochemical genetics · 2025Article
- Ionizing radiation-induced disruption of Rela-Bclaf1-spliceosome regulatory axis in primary spermatocytes causing spermatogenesis dysfunction.Cell communication and signaling : CCS · 2025Article
- BCLAF1 Regulates Osteoarthritic Cartilage Degradation Through Interaction with LAMTOR2.International journal of biological sciences · 2025Article
- A distinct metabolic and epigenetic state drives trained immunity in HSC-derived macrophages from autoimmune mice.Cell stem cell · 2024Article
- BCLAF1 is Expressed as a Potential Anti-oncogene in Bile Duct Cancer.Biochemical genetics · 2024Article
- Single-Cell Patch-Clamp/Proteomics of Human Alzheimer's Disease iPSC-Derived Excitatory Neurons Versus Isogenic Wild-Type Controls Suggests Novel Causation and Therapeutic Targets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Originally identified as a regulator of apoptosis and transcription, B-cell lymphoma-2-associated transcription factor 1 (BCLAF1) has since been shown to be associated with a multitude of biological processes, such as DNA damage response, splicing and processing of pre-mRNA, T-cell activation, lung development, muscle cell proliferation and differentiation, autophagy, ischemia-reperfusion injury, and viral infection. In recent years, an increasing amount of evidence has shown that BCLAF1 acts as either a tumor promoter or tumor suppressor in tumorigenesis depending on the cellular context and the type of cancer. Even in the same tumor type, BCLAF1 may have opposite effects. In the present review, the subcellular localization, structural features, mutations within BCLAF1 will be described, then the regulation of BCLAF1 and its downstream targets will be analyzed. Furthermore, the different roles and possible mechanisms of BCLAF1 in tumorigenesis will also be highlighted and discussed. Finally, BCLAF1 may be considered as a potential target for cancer therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.